Fiche centre
Ulyanovsk Regional Clinical Hospital
Ulyanovsk — Russia
Essais liés6clinical trials
VilleUlyanovsklocalisation
PaysRussialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06675955
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 3 | NCT06675955 | OleroMAX — An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04544436 | MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |
| IMU-838 tablets | SEP | Phase 3 | NCT05201638 | ENSURE-2 — Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04586010 | FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |